Drugs & Targets Oncomine Dx Target Test receives FDA approval as first NGS-based companion diagnostic for RET fusion + NSCLC September 11, 2020Vol.46 No.34
Drugs & Targets FDA issues alert about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer September 11, 2020Vol.46 No.34
Drugs & Targets Oncocyte receives final pricing decision for DetermaRx Molecular Test for lung cancer from CMS September 11, 2020Vol.46 No.34
Drugs & Targets MD Anderson, Xencor collaborate on investigational XmAb drug candidates September 11, 2020Vol.46 No.34
Drugs & Targets Onureg oral therapy receives FDA approval for continued treatment for adults in first remission with AML September 04, 2020Vol.46 No.33
Drugs & Targets Kyprolis and Darzalex receives FDA approval for combination therapy for multiple myeloma September 04, 2020Vol.46 No.33
Drugs & Targets Blenrep receives FDA approval in relapsed or refractory multiple myeloma September 04, 2020Vol.46 No.33
Drugs & Targets Guardant360 CDx assay receives FDA approval as first liquid biopsy NGS companion diagnostic test September 04, 2020Vol.46 No.33
Drugs & Targets ClonoSEQ assay receives expanded FDA clearance to assess MRD in CLL September 04, 2020Vol.46 No.33
Drugs & Targets Melflufen receives FDA Priority Review for triple-class refractory multiple myeloma September 04, 2020Vol.46 No.33
